A
grade
NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.
Kisspeptin (KP-10) · Human vaccines & immunotherapeutics · 2026 · RCT · Phase 4 · n=176
Bivalent mRNA vaccines showed the highest neutralization levels against the KP.2 subvariant shortly after the booster, but all vaccine types had similar neutralization levels by 12 months.
50% neutralization titers against strain XBB.1.16 boosted by 3.2-fold in monovalent mRNA, 4.1-fold in bivalent mRNA, and 1.6-fold in NVX-CoV2373 at day 28.